and could provide coordination among the several Government agencies that support and conduct this research. Further, such a committee may suggest appropriate administrative and legislative proposals where warranted. I have asked Dr. Donald S. Fredrickson, Director of the NIH, to serve as Chairman for this committee. I would very much appreciate your forwarding your representative's name to Dr. Fredrickson at NIH, Building 1, Room 124, Bethesda, Maryland 20014, by October 15. If you wish, you may designate more than one representative from your Department. At Senate hearings on the NIH guidelines held on September 22, Dr. Fredrickson stressed that, if possible, a meeting of the Interagency Committee would be held in October to review application of guidelines to the public and private sectors. Your prompt attention to this matter will be deeply appreciated. The public policy issues that the Interagency Committee will address are Thank you very much for your cooperation. Cordially, Secretary CHARTER INTERAGENCY COMMITTEE ON RECOMBINANT DNA RESEARCH Purpose To coordinate Federal programs and activities relating to recombinant deoxyribonucleic acid (DNA) research, to assist in facilitating compliance with a uniform set of guidelines for the conduct of this research in the public and private sectors and to facilitate communication and exchange of information among Government agencies. Authority This Committee is established pursuant to a memorandum of September 22 from the President to all Department and Agency Heads and a letter of October 1 from the Secretary of Health, Education, and Welfare. This Committee is excluded from provisions of Public Law 92-463 which sets forth standards for the formation and use of Advisory Committees. Function The Interagency Committee on Recombinant DNA Research shall advise the Secretary, the Assistant Secretary for Health, and the Director, National Institutes of Health, on the coordination of those aspects of all Federal programs and activities relating to recombinant DNA research. The Committee shall provide for the full communication and exchange of information necessary to maintain adequate coordination of such programs and activities. The Committee shall be responsible for facilitating compliance with a uniform set of guidelines in the conduct of this research in the public and private sectors and, where warranted, suggest administrative or legislative proposals. Structura The Director of the National Institutes of Health shall serve as Chairman of the Committee and the Committee shall include representation from all Departments and Agencies whose programs involve health functions or responsibilities as determined by the Secretary. Departments and Agencies which shall have representation on this Constituent Agencies of KEW: Office of the Assistant Secretary for Health Food and Drug Administration Other Departments and Agencies: Meetings Department of Interior Department of Justice Department of Labor Department of State Department of Transpor ation Council on Environment il Quality Energy Research and Development Administration National Aeronautics and Space Administration Nuclear Regulatory Commission Office of Science and Technology Policy The Committee shall meet at the call of the Chairman but not less often than four times a year. Heetings shall be conducted and records of proceedings kept, as required by applicable laws and departmental regulations. Compensation All members will be full-time Federal employees who are allowed travel expenses plus per diem for subsistence while serving away from their duty stations in accordance with Standard Government Travel Regulations. Annual Cost Estimate Estimated cost of operating the Committee excluding staff support is $1,000. Estimated cost of annual staff support is two man-yeers at $40,000. Reports The Committee shall prepare a report for the Secretary not later than sixty days after the end of each fiscal year, which shall include: a description of the work of the Committee in coordinating DNA research activities in the public and private sectors, a description of the work of the Committee in promoting the coordination of Federal programs and activities relating to recombinant DNA research, and recommendations for assuring implementation of a standard set of guidelines to govern the conduct of this research nationally. A copy of the report shall be provided to the Department Committee Management Officer. Termination Date Unless renewed by appropriate action prior to its expiration, the Interagency Committee on Recombinant DNA Research will terminate two years from date of establishment. APPROVED: Date Secretary |